NEW YORK (360Dx) – A decades-old biomarker that detects about 40 percent of pancreatic cancers could play a more effective role in screening high-risk patients for the disease when it is combined with a glycan biomarker, sTRA, according to a research group developing the test.

Van Andel Research Institute is leading the development of the new approach that in a recent study detected nearly 70 percent of pancreatic cancers with a less than 5 percent false-positive rate.